Rotator Cuff Tendon Repair With FiberLocker System Patch Augmentation
NCT ID: NCT07005063
Last Updated: 2025-07-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
50 participants
INTERVENTIONAL
2025-07-03
2029-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
FiberLocker® System Augmentation of Rotator Cuff Repairs
NCT06918041
Patch Study (Patch-augmented Rotator Cuff Repair)
NCT06076902
Rotator Cuff Tears Repair With or Without Dermal Patch Augmentation
NCT04975581
Prospective Study to Determine the Safety and Effectiveness of a Connective Tissue Allograft Active Matrix (AM) vs. Standard of Care in Arthroscopic Rotator Cuff Repair
NCT05894265
Regeneten Patch vs Standard Care in Partial Thickness Rotator Cuff Repair
NCT04673344
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Augmentation of Rotator Cuff Repair using the FiberLocker System
All enrolled participants will undergo repair of the rotator cuff tear, with augmentation utilizing the FiberLocker System.
FiberLocker® System (encompassing SpeedPatch® PET and FiberLocker Instrument® SN)
The FiberLocker® System is a mechanical augmentation system that includes an implant (SpeedPatch® PET) and an instrument (FiberLocker® Instrument SN) for its attachment. The implant is composed of non-woven PET fibers, and the instrument features a reciprocating needle at its tip, which pushes the individual patch fibers into the underlying tendon tissue
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
FiberLocker® System (encompassing SpeedPatch® PET and FiberLocker Instrument® SN)
The FiberLocker® System is a mechanical augmentation system that includes an implant (SpeedPatch® PET) and an instrument (FiberLocker® Instrument SN) for its attachment. The implant is composed of non-woven PET fibers, and the instrument features a reciprocating needle at its tip, which pushes the individual patch fibers into the underlying tendon tissue
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Full-thickness tear of the supraspinatus or combined infraspinatus and supraspinatus
3. The rotator cuff tear is of traumatic origin.
4. Subject is ≥ 40 years of age \& ≤ 65 years of age.
5. Primary rotator cuff repair
6. Informed Consent signed by the subject
7. Pre-operative MRI performed
Exclusion Criteria
2. Subjects who do not have the power of judgement or are unable to fully understand all aspects of the investigation that are relevant to the decision to participate
3. Participation in another investigation with an investigational drug or another MD within the 30 days preceding and during the present investigation,
4. Previous enrolment into the current investigation,
5. Enrolment of the PI, his/her family members, employees and other dependent persons,
6. Inability to follow the procedures of the investigation, or known or suspected non-compliance, e.g. due to language problems, psychological disorders, dementia, drug or alcohol abuse, etc. of the subject
7. Active smoker
8. History of claustrophobia that would prevent an MRI of the index shoulder
9. Presence of an implanted metallic device or other implants that would contraindicate acquisition or inhibit radiologist review of an MRI of the index shoulder
10. Pregnant or planning to become pregnant during the study period
11. Breast feeding women
12. Subject has conditions or circumstances that would interfere with study requirements.
13. Contraindications and limitations of the MD as described in the IFUs.
14. Partial rotator cuff tears
15. History or known allergy or intolerance to polyester
16. Complete full-thickness subscapularis tears greater than the superior 1/3 of the tendon, with Lafosse grade 3 or greater
17. Massive rotator cuff tears, tear size equal to or greater than 4 cm in the anterior-posterior dimension or irreparable rotator cuff tear
18. Limited space or exposure for implant delivery
19. Structural or pathological condition of the bone or soft tissue that could impair healing.
20. Intraoperative rotator cuff tear characteristics differ from preoperatively expected characteristics and fulfil one of the abovementioned criteria
21. Fatty infiltration of the index shoulder rotator cuff muscle \> Goutallier Score 2
22. Corticosteroid injection in the operative shoulder within 6 weeks of operation
23. Subject shows frozen shoulder/adhesive capsulitis at day of surgery
24. Cases of moderate to severe osteoarthritis
25. Patients with inflammatory disease or auto-immune based joint diseases (e.g., rheumatoid arthritis, systemic lupus erythematosus, arthropathy)
26. Subjects with diabetes type I or II
27. The subject currently has an acute infection in the area surrounding the surgical site
28. Evidence of active infection, osteomyelitis, sepsis or distant infection which could spread to the index joint.
29. Any comorbidity or condition that renders the patient a poor surgical candidate as determined by the Investigator.
40 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
ZuriMED Technologies AG
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Balgrist University Hospital
Zurich, Canton of Zurich, Switzerland
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SNCTP000006378
Identifier Type: OTHER
Identifier Source: secondary_id
ZM072024
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.